Open AccessComparing paclitaxel-platinum with ifosfamide-platinum as the front-line chemotherapy for patients with advanced-stage uterine carcinosarcoma
Author(s) -
Ming-Hsuan Su,
Hsiang Ling Wu,
Hsin-Yi Huang,
Na-Rong Lee,
Wen-Hsun Chang,
ShihChieh Lin,
Yi Jen Chen,
Peng-Hui Wang
Publication year - 2022
Publication title -
journal of the chinese medical association
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.535
H-Index - 42
eISSN - 1728-7731
pISSN - 1726-4901
DOI - 10.1097/jcma.0000000000000643
Subject(s) - medicine , ifosfamide , regimen , chemotherapy , surgery , univariate analysis , stage (stratigraphy) , paclitaxel , oncology , urology , multivariate analysis , cisplatin , paleontology , biology
Uterine carcinosarcoma (UCS) is a rare but highly lethal disease. Adjuvant chemotherapy is highly recommended for advanced UCS. To date, the standard chemotherapy regimen is still uncertain, although two regimens as paclitaxel-platinum (PP) and ifosfamide-platinum (IP) regimens are most commonly used. The aims of the current study attempt to compare both regimens in the management of advanced UCS patients.